Factor Xa is highly protected from antithrombin-fondaparinux and antithrombin-enoxaparin when incorporated into the prothrombinase complex.
about
New anticoagulants for the prevention and treatment of venous thromboembolismNew insights into the biology of tissue factor pathway inhibitorEvaluation of the efficacy and safety of rivaroxaban using a computer model for blood coagulationLatest medical treatment strategies for venous thromboembolism.Anticoagulation by factor Xa inhibitors.FEIBA: mode of action.Inhibition of the prothrombinase complex on red blood cells by heparin and covalent antithrombin-heparin complexTissue factor pathway inhibitor-alpha inhibits prothrombinase during the initiation of blood coagulation.Factor Xa activation of factor V is of paramount importance in initiating the coagulation system: lessons from a tick salivary protein.Rivaroxaban: a novel, oral, direct factor Xa inhibitor.Heparin rescues factor V Leiden-associated placental failure independent of anticoagulation in a murine high-risk pregnancy model.Laboratory assessment of new anticoagulants.New oral anticoagulants: a view from the laboratory.What did we learn from new oral anticoagulant treatment?Pro- and anticoagulant factors facilitate thrombin generation and balance the haemostatic response to FEIBA(®) in prophylactic therapy.A single test to assay warfarin, dabigatran, rivaroxaban, apixaban, unfractionated heparin, and enoxaparin in plasma.Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies.
P2860
Q24681351-070BBF85-A84B-43A1-87FE-EAF50C233535Q26865048-7C127A63-5520-4382-B3F2-F45D20B291B7Q28477868-67163247-74CD-474F-B79F-2962C470F85AQ33375535-51F98DFD-8064-4BD1-B8D5-70D715D61518Q34130097-F9F2EA6D-81BC-402D-92B4-51811F1933CEQ35895858-9E419CB9-8DE8-4704-8264-5FC11F348CF2Q36481982-81D73562-A103-4D88-9DC8-11F02FB98956Q37276726-56499157-7237-407E-905C-949C18029F72Q37303864-D438F589-7EA7-452F-8E2B-8E7EE527D520Q37377940-86FE0E41-D715-4370-B5B1-ADAE3B5F910CQ37634740-FEEFD379-8A09-4466-8C56-E0AAD9D66B9BQ37834646-064018C5-4BEC-4253-83D3-2F8B66CEFA9FQ37992582-D9FE149E-C146-46D8-B8DE-15E58CBA59E4Q38048533-6EF1AE6C-0084-4C4D-8EAA-97E425DCBA02Q39995569-CE5C2117-A6D9-430F-A5CA-870464810370Q46303154-44F59770-8F82-4280-A566-DF110D8400EDQ46722053-DFF5A15A-C370-4649-AE74-8F41C8CDD4E7
P2860
Factor Xa is highly protected from antithrombin-fondaparinux and antithrombin-enoxaparin when incorporated into the prothrombinase complex.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Factor Xa is highly protected ...... to the prothrombinase complex.
@en
Factor Xa is highly protected ...... to the prothrombinase complex.
@nl
type
label
Factor Xa is highly protected ...... to the prothrombinase complex.
@en
Factor Xa is highly protected ...... to the prothrombinase complex.
@nl
prefLabel
Factor Xa is highly protected ...... to the prothrombinase complex.
@en
Factor Xa is highly protected ...... to the prothrombinase complex.
@nl
P2093
P2860
P1476
Factor Xa is highly protected ...... to the prothrombinase complex.
@en
P2093
P2860
P304
P356
10.1046/J.1538-7836.2003.00254.X
P577
2003-06-01T00:00:00Z